Study of TQB2450 plus progestin for uterine cancer patients wanting to keep fertility
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of an immunotherapy drug (TQB2450) with a hormone treatment (progestin) for patients with a specific type of early-stage uterine cancer who wish to preserve their ability to have children. The goal is to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You have been diagnosed with endometrioid endometrial cancer that is low grade (grade 1 or 2) and has not invaded deep into the uterine muscle.
- Your cancer shows a specific genetic feature called MMR deficiency (MMRd).
- You want to preserve your fertility or keep your uterus.
- You have not had prior treatment with high-dose progesterone or certain oral contraceptives for more than 1 month in the last 3 months.
- You do not smoke more than 15 cigarettes per day.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This trial tests a combination of two investigational drugs—anlotinib (a capsule that blocks blood supply to tumors) and TQB2450 (an immunotherapy that helps your immune system attack cancer cells)—for people with recurrent or metastatic endometrial cancer that has not responded to previous platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow their growth.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This trial tests a new targeted drug, TQB2102, for women with advanced or recurrent gynecologic cancers that have some HER2 protein. It may be an option if your cancer has continued to grow after platinum chemotherapy.
This trial looks at a fertility-preserving treatment plan for people with early-stage endometrial cancer who want to keep the ability to have children. It may help you avoid surgery that removes fertility, if you meet the trial’s safety and eligibility rules.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.